TAVI specific sex consideration

Giulia Masiero¹, Valeria Paradies², Anna Franzone³, Barbara Bellini⁴, Chiara De Biase⁵, Nicole Karam⁶, Francesca Sanguineti⁷, Hélène Eltchaninoff⁸, Chiara Fraccaro¹, Alaide Chieffo⁶

¹Department of Cardiac, Thoracic, Vascular Science and Public Health, University of Padova, Padova 35128, Italy.
²Department of Cardiology, Maasstad Hospital, Rotterdam 3079, Netherlands.
³Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples 80125, Italy.
⁴Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy;
⁵Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse 31076, France;
⁶Cardiology Department, European Hospital Georges Pompidou, Paris 75015, France;
⁷Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques CARTIER, Massy 91300, France;
⁸Normandie University, UNIROUEN, U1096, CHU Rouen, Department of Cardiology, Rouen F-76000, France.

Correspondence to: Prof. Alaide Chieffo, Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, 60, Via Olgettina, Milan 20132, Italy. E-mail: chieffo.alaida@hsr.it


Received: 31 Aug 2021 First Decision: 26 Nov 2021 Revised: 5 Dec 2021 Accepted: 14 Dec 2021 Published: 6 Jan 2022

Academic Editor: Andrea Scotti Copy Editor: Xi-Jun Chen Production Editor: Xi-Jun Chen

Abstract

The impact of sex on baseline characteristics and morphological and clinical presentation of degenerative aortic stenosis has been widely demonstrated but poorly understood. Moreover, differently from valve surgery, where patients were predominantly male, both sexes have been well represented in percutaneous treatment of aortic stenosis (AS), and women appeared to derive greater benefit with transfemoral aortic valve implantation (TAVI) compared to surgical treatment. This review focuses on sex-specific differences in epidemiology, pathophysiology, diagnostic issues, treatment options, and clinical outcomes of degenerative AS. Moreover, we evaluate how sex-based TAVI management, from device selection to procedural tricks, may affect outcomes.

Keywords: Transcatheter aortic valve implantation, aortic stenosis, sex-specific differences, device selection, clinical management

INTRODUCTION

Although sex differences in coronary artery disease have been well appreciated, the impact of sex on valvular heart disease (VHD) has not been extensively discussed. Degenerative aortic stenosis (AS) currently
represents one of the most common VHD conditions. Men and women demonstrate dissimilar baseline characteristics, morphological and clinical presentation, and outcomes\cite{1}. Different from valve surgery, where patients were predominantly male, both sexes have been well represented in percutaneous treatment of AS\cite{2}. Furthermore, women appeared to derive greater benefit compared to men with transfemoral aortic valve implantation (TAVI) compared to surgical treatment. This review focuses on sex-specific differences in the clinical management of degenerative AS, highlighting sex-specific technical considerations in the percutaneous treatment of the disease, taking into account the latest technological innovations. In particular, epidemiology, pathophysiology, diagnostic issues, treatment options, and clinical outcomes in the female AS population are reported. Moreover, we evaluate whether a sex-based TAVI management, from device selection to procedural tricks, might have an impact on clinical outcomes.

**SEX-SPECIFIC CONSIDERATION IN THE DIAGNOSIS AND TREATMENT OF AS**

**Epidemiology of AS**

AS is the most prevalent valvular heart disease requiring intervention, surgery or transcatheter, in Europe and North America\cite{3,4}. The prevalence of AS is 4% by echocardiography, with equal frequency in men and women and a mortality rate of over 50% at two years in symptomatic AS patients unless promptly treated. It occurs primarily as a consequence of degenerative calcific disease, so its prevalence is rising rapidly due to the aging population; it has been estimated that approximately 12% (Europe) and 4% (North America) of the elderly patients (> 75 years) have symptomatic severe AS\cite{5}. Conversely, among the most frequent congenital anomalies, bicuspid aortic valve (BAV) is 3-4 times more prevalent in men as compared to women and is associated with earlier accelerated degeneration of the valve apparatus that tends to be more severe than in tricuspid aortic valve\cite{4}. Although the evidence on the distribution of BAV phenotypes between sexes is not consistent, observational series showed higher prevalence of stenotic dysfunction in female patients compared to men more frequently affected by aortic regurgitation\cite{4}. As rigorous evidence is still lacking in the percutaneous treatment of BAV, we focus our discussion on tricuspid aortic valve stenosis.

**Pathophysiology of degenerative AS**

It is now recognized that degenerative age-related valve mineralization is a dynamic process with lipid accumulation, chronic inflammation, and active valve leaflet calcification. It involves proinflammatory monocytes and activated endothelial cells that stimulate macrophage accumulation, proteolytic enzymes release, and the differentiation of myofibroblasts and smooth muscle cells into osteoblasts with resultant osteogenic activity. However, little is known about the role of sex in the etiology and progression of the disease.

To date, sex differences in the valves and the ventricular response to the pressure and volume overload due to valvular disease have not been completely elucidated [Figure 1]. A lower collagen I-II and matrix metalloproteinase 2 gene expression has been found in women vs. men in the interstitial cells of myocardial biopsy specimens performed at the time of surgery; adjunctively, on a molecular level, decreased extracellular fibrosis has been linked to the protective effect of estrogen in the female population. Therefore, women display different patterns of hypertrophy and remodeling, with a different extent of ventricular fibrosis and morphology of aortic valve disorder\cite{3}. As a matter of fact, differently from males, women showed more frequent concentric left ventricular (LV) hypertrophy, smaller LV cavities, and greater relative wall thicknesses facing the increased afterload of worsening AS. However, women more often experience reversal of hypertrophy shortly after aortic valve replacement\cite{6}. Moreover, studies comparing the extent of aortic valve calcification (AVC) measured by multidetector computed tomography (MDCT) in men and women with comparable degrees of AS revealed a lower AVC load, even after adjustment for body surface area and echocardiographic parameters\cite{6}. Likewise, female sex was correlated to lower AVC progression
with no difference in the hemodynamic progression of the disease, probably due to a more pronounced fibrotic remodeling than men. Several studies showed the presence of higher levels of valvular fibrosis and dense connective tissue at the same degree of hemodynamic stenosis severity in women compared to men.[7]

There are conflicting data on the sex differences in the natural progression of AS.[8] Cramariuc et al.[9] reported similar progression of the aortic disease between men and women with respect to mean gradient, velocity, or valve area. Conversely, in the COFRASA-GENERAC study, female sex was an independent predictor of aortic valve calcification and mean gradient progression, showing a significant association with AS-related event rates at long-term follow-up.[10]

The effect of sex, as an important modulator of pathological processes associated with the development of AS, remains largely unexplored. Its comprehension remains extremely important, since it determines the development of different clinical phenotypes and following prognosis in men and women.

Clinical presentation
In patients presenting with AS, the sex discrepancy starts in the pathophysiology of the disease at valvular and ventricular levels and includes different calcification processes, fibrosis, and response to AS hemodynamic burden. Nevertheless, the clinical differences between men and women with AS and their link to management and outcomes remain poorly defined.[7,11,12] Increasing awareness of sex-related differences in clinical presentation and diagnosis translates into better characterization and decision-making strategies for this subset of patients with consequent improvement in clinical outcomes [Figure 2]. Women tend to present later; this often leads to a lower referral to treatment. Almost half of women with severe AS are asymptomatic, with a 1.0%-1.5% yearly rate of sudden cardiac death.[13] Women are diagnosed at later ages, with fewer comorbidities, and have more symptoms than men.[12] When symptoms appear, women are likely to have a higher rate of symptomatic heart-failure (New-York Heart Association class III-IV), with shortness of breath and dizziness/syncope as most frequent symptoms, and greater prevalence of chronic kidney disease.[14] The higher symptomatic burden in women may be explained by the higher relative wall thickness, a smaller LV cavity, and higher wall stress and filling pressures than men in the context of AS.
chronic pressure overload\cite{15,16,17}. Per contra, men present with a higher prevalence of coronary artery disease, peripheral artery disease, and diabetes\cite{8}. Considering that symptoms onset is a key factor in determining the timing of treatment, it is, therefore, relevant to take into account both clinical symptoms and imaging findings for decision-making strategy\cite{4}.

**Diagnosis of AS**

Experts have questioned the lack of consistent sex-specific criteria in guidelines for the grading of disease severity. Echocardiographic criteria for the diagnosis of AS guarantee indexed values for body surface area (BSA) [aortic valve area (AVA) < 0.6 cm$^2$/m$^2$], an important distinction for women; however, the same does not apply for other hemodynamic parameters such as mean gradient or peak velocity\cite{4,11}. However, transthoracic echocardiogram (TTE) does not allow for an accurate AVC and AVA quantification as the continuity equation may underestimate the LV outflow tract (LVOT) area and stroke volume, resulting in discrepancy between mean gradient and AVA\cite{18,19}. Moreover, approximately 30%-55% of patients with severe AS have low flow-low gradient stenosis on echo. In 10%-25% of these patients, more commonly women, small, restrictive LV cavity, greater arterial stiffness, and higher ventriculoarterial impedance result in “paradoxical” underestimation of the severity of the AS [paradoxical low-flow/low-gradient (LFLG) AS] despite preserved LV systolic function\cite{20}.

While echo remains the standard diagnostic test, cardiac magnetic resonance (cMR) and MDCT could provide complementary information on LV function and aortic valve calcification, respectively [Figure 2]. cMR allows identification of different patterns of hypertrophy and remodeling and extent of LV fibrosis at late gadolinium enhancement assessment\cite{21}. MDCT could be used to provide more specific and detailed quantification of AVC severity and AS progression\cite{22,23,24}. An integrated approach based on TTE and MDCT should be considered for reclassification of AVA, using the true MDCT measured LVOT area\cite{25}. AVC load
has been suggested as a surrogate marker of prognostic importance in AS patients as strongly associated with worse morbidity and mortality.\textsuperscript{[26-30]} MDCT data of AS patients support sex-related differences in the levels of AVC load required to reach hemodynamically severe AS.\textsuperscript{[8]}. For the same degree of AS severity, women have a lower AVC load compared with men, also after adjustment for BSA, resulting in sex-specific calcium scores for the diagnosis of AS.\textsuperscript{[8,31,32]} They have a more fibrotic remodeling of the aortic valve with higher levels of valvular fibrosis and dense connective tissue at the same degree of hemodynamic stenosis severity, while men have a more calcific remodeling, irrespective of patients’ age.\textsuperscript{[33]} These discordant calcific/fibrotic patterns between men and women may be exacerbated by specific valve morphology. Women with stenotic bicuspid aortic valve have less calcification than men for the same hemodynamic severity of AS, as well as less calcification than women with stenosed tricuspid aortic valve.\textsuperscript{[32]} Interestingly, despite lower AV calcium, women have more significant progression of AVC over three years of follow-up.\textsuperscript{[10]} This imbalance in clinical presentation and pathophysiological process should be brought to the attention of the cardiology community to ensure equivalent care for AS in men and women. Due to the different onset of symptoms and the different pathophysiological mechanisms, AS classification in women may further benefit from an integrated TTE and MDCT diagnostic approach in order to avoid late referral and adverse outcomes.

**Treatment choice**

In patients with severe symptomatic AS, valve replacement has a beneficial impact on survival, symptoms, and left ventricular function.\textsuperscript{[34]} The choice between surgical aortic valve replacement (SAVR) and transcatheter intervention is based on patient’s age and clinical and anatomic features.\textsuperscript{[35]} International guidelines do not include specific recommendations for AS treatment according to sex. However, historically, women have been more often than men denied for SAVR.\textsuperscript{[34,36]} Several reasons account for this unequal referral pattern: compared with men, women with AS feature older age, atypical symptoms, and more advanced cardiac disease despite preserved left ventricular ejection fraction.\textsuperscript{[37]} In addition, men have higher prevalence of concomitant coronary artery disease requiring coronary artery bypass grafting, and physicians usually overestimate the operative risk of female patients by perceiving a greater risk related to their physical frailty.\textsuperscript{[38]} This sex gap has partially narrowed with the widespread adoption of TAVI, as women represent more than 50% of the treated population.\textsuperscript{[39]} The heart team plays a pivotal role in the selection of the optimal modality of intervention (surgical or transcatheter) based on several features and avoiding futility, especially for TAVI.\textsuperscript{[40]} Female sex is a risk factor for perioperative mortality in both the EuroSCORE and the Society of Thoracic Surgeons Risk Score. However, sex is not listed among factors that could preferentially drive the choice between SAVR and TAVI. Historically, at the time of intervention, women present with advanced age at presentation and greater prevalence of higher frailty that potentially increases the risk of procedural complications and delays recovery after surgical intervention.\textsuperscript{[34]} Despite the augmented incidence of adverse vascular events that are discussed below [Table 1], several further factors make female patients preferential candidates for TAVI than SAVR, including the lower prevalence of concomitant severe coronary artery disease and the lower occurrence of patient-prosthesis mismatch and paravalvular regurgitation despite small aortic annulus.\textsuperscript{[4]} However, considering their longer life expectancy, assessing TAVI durability is of paramount importance even in higher risk cohorts. Long-term clinical results (> 10 years) on cardiovascular mortality, need of reintervention, and bioprosthetic valve failure (BVF) according to type treatment (surgical vs. percutaneous) and bioprosthesis (balloon vs. self-expandable) are needed. In particular, the impact of sex on structural and non-structural mechanisms of valve deterioration still needs to be clarified. To date, only anecdotal observational experiences identified female sex, small BSA, and smaller size of THV as possible predictors of BVF.\textsuperscript{[40]}
Table 1. Main characteristics and results of studies comparing TAVI outcomes in women and men

<table>
<thead>
<tr>
<th>Study/first author (Ref.)</th>
<th>Design</th>
<th>Overall population (n)</th>
<th>% women</th>
<th>Balloon-expanding valves (%)</th>
<th>Self-expanding valves (%)</th>
<th>Follow-up</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRANCE 2 Registry(87)</td>
<td>Prospective observational</td>
<td>3972</td>
<td>49.5</td>
<td>73.2</td>
<td>26.8</td>
<td>1 year</td>
<td>Similar rate of mortality at 1 month (9.5% vs. 9.2%) and lower rate at 1-year than men (19.3% vs. 23.7%)</td>
</tr>
<tr>
<td>Kodali et al.(86)</td>
<td>Analysis of RCT</td>
<td>2559</td>
<td>47.6</td>
<td>100</td>
<td>0</td>
<td>1 year</td>
<td>Higher rate of vascular complications (17.3% vs. 10%) and bleeding (10.5% vs. 7.7%) in women than men; similar 30-day mortality and lower 1-year mortality (19% vs. 25.9%)</td>
</tr>
<tr>
<td>Szerlip et al.(50)</td>
<td>Analysis of RCT</td>
<td>1661</td>
<td>39.5</td>
<td>100</td>
<td>0</td>
<td>1 year</td>
<td>No difference in mortality at 30 days (2% vs. 1.2%) and 1-year (9.3% vs. 10.2%). Higher rates of major vascular complications in women (7.9% vs. 4.4%)</td>
</tr>
<tr>
<td>Sannino et al.(87)</td>
<td>Retrospective observational</td>
<td>910</td>
<td>46.5</td>
<td>57.7</td>
<td>42.3</td>
<td>1 year</td>
<td>Higher rates of major vascular complications (7.8% vs. 4.1%) and bleeding (4% vs. 1.6%) in women. Lower rates of mortality at 1-year (7% vs. 12.7%)</td>
</tr>
<tr>
<td>Doshi et al.(88)</td>
<td>Retrospective observational</td>
<td>41,050</td>
<td>47.7</td>
<td>NA</td>
<td>NA</td>
<td>In-hospital</td>
<td>Higher rates of mortality (4.7% vs. 3.9%) in women</td>
</tr>
<tr>
<td>Stehli et al.(89)</td>
<td>Prospective observational</td>
<td>683</td>
<td>58</td>
<td>10.4</td>
<td>89.6</td>
<td>1 year</td>
<td>Higher rates of major bleeding (3.3% vs. 1%) and 30-day mortality (2.4% vs. 0.3%) in women. Similar rates of 1-year mortality (8.3% vs. 7.8%)</td>
</tr>
<tr>
<td>FRAILTY-AVR(38)</td>
<td>Prospective observational</td>
<td>759</td>
<td>44.8</td>
<td>NA</td>
<td>NA</td>
<td>1 year</td>
<td>Higher rates of 30-day mortality and major vascular complications in women. Similar rates of 1-year mortality (19% vs. 17%).</td>
</tr>
<tr>
<td>TVT Registry(90)</td>
<td>Prospective observational</td>
<td>23,652</td>
<td>49.9</td>
<td>88.5</td>
<td>11.5</td>
<td>1 year</td>
<td>Higher rates of vascular complications (8.3% vs. 4.4%) and bleeding (8% vs. 5.9%) in women. Lower rates of 1-year mortality (21.3% vs. 24.5%).</td>
</tr>
<tr>
<td>Forrest et al.(91)</td>
<td>Analysis of RCT</td>
<td>3687</td>
<td>46.3</td>
<td>0</td>
<td>100</td>
<td>1 year</td>
<td>Higher rates of vascular complications (9.7% vs. 4.9%) and bleeding (29.7% vs. 21.7%) in women. Similar rates of 30-day (5.9% vs. 5.8%) and 1-year mortality (21.3% vs. 24.5%).</td>
</tr>
<tr>
<td>D’Ascenzo et al.(92)</td>
<td>Retrospective observational</td>
<td>377</td>
<td>57.2</td>
<td>NA</td>
<td>NA</td>
<td>2 years</td>
<td>Higher rates of bleeding (4.4% vs. 2.5%) and major vascular complications (12.9% vs. 9.8%). Similar rates of death at 30-day and longest follow-up</td>
</tr>
<tr>
<td>Italian Multicenter CoreValve registry(93)</td>
<td>Prospective observational</td>
<td>659</td>
<td>55.8</td>
<td>N/A</td>
<td>100</td>
<td>13 months</td>
<td>No significant differences in peri-procedural event rates and mortality</td>
</tr>
<tr>
<td>Humphries et al.(94)</td>
<td>Analysis of RCT</td>
<td>641</td>
<td>51.3</td>
<td>100</td>
<td>0</td>
<td>2 years</td>
<td>Higher rates of bleeding (21.6% vs. 15.8%) and major vascular complications (12.4% vs. 5.4%). Lower rates of 30-day (6.5% vs. 11.2%) and 2-year mortality (27.9% vs. 38.3%)</td>
</tr>
<tr>
<td>Czarnecki et al.(95)</td>
<td>Retrospective observational</td>
<td>999</td>
<td>45.3</td>
<td>57.1</td>
<td>38</td>
<td>1 year</td>
<td>Higher rates of bleeding (14.5% vs. 12.6%) and major vascular complications (18.7% vs. 16.7%). Similar rates of 30-day and 1-mortality</td>
</tr>
<tr>
<td>Katz et al.(81)</td>
<td>Prospective observational</td>
<td>819</td>
<td>51</td>
<td>67.7</td>
<td>28.9</td>
<td>1 year</td>
<td>Higher rates of bleeding (11% vs. 3.8%), major vascular complications (11.2% vs. 5.5%), and mortality at 30 days (11.5% vs. 6.5%). Similar rates of 1-year mortality (29.7% vs. 25.9%)</td>
</tr>
</tbody>
</table>

TAVI: Transcatheter aortic valve implantation; RCT: randomized control trial.
Impact of sex on clinical outcomes

Overall, the impact of sex on clinical outcomes after SAVR or TAVI is not clearly defined. Higher rates of mortality and peri-procedural complications have been reported among women than men receiving SAVR. In the Italian Observational Multicenter Registry (OBservA Valve N-TACTical Randomized Evaluation – OBSERVANT), female sex was an independent predictor for risk-adjusted 30-day mortality [odds ratio (OR) = 2.34; \( P = 0.043 \)] and transfusions (OR = 1.47; \( P = 0.003 \)) after SAVR\(^{[46]}\). In a propensity-matched analysis from the Nationwide Inpatient Sample, in-hospital mortality was significantly higher in women compared with men following SAVR (3.3\% vs. 2.9\%, \( P < 0.001 \)); they also had higher rates of vascular complications and blood transfusions\(^{[42]}\). Other studies did not find sex-related differences in short- and long-term mortality after SAVR or reported better outcomes in women\(^{[43-46]}\). In the Women’s INInternational Transcatheter Aortic Valve Implantation (WIN TAVI) registry, the first study that specifically assessed the performance of TAVI in a population of solely women (\( n = 1019 \)), the primary Valve Academic Research Consortium (VARC)-2 early safety endpoint at 30 days (composite of mortality, stroke, major vascular complications, life-threatening bleeding, stage 2 or 3 acute kidney injury, coronary artery obstruction, or repeat procedure for valve-related dysfunction) was 14\% with a low incidence of early mortality (3.4\%) and stroke (1.3\%)\(^{[45]}\). In addition, the VARC-2 efficacy endpoint (composite of mortality, stroke, myocardial infarction, hospitalization for valve-related symptoms or heart failure, or valve-related dysfunction) occurred in 10.9\% and 16.5\% of patients at 30 days and 1 year, respectively, and 1-year survival was better than in men\(^{[46]}\). The results of other observational studies and subgroups analysis of randomized trials that evaluated the impact of sex on clinical outcomes after TAVI are summarized in Table 1. Overall, in these studies, compared with men, women were older and with fewer comorbidities; they had higher rates of procedure-related vascular complications and bleeding, and they had comparable or even better survival at early and long term. Similarly, a patient-level data meta-analysis of 11,310 patients reported higher rates of major vascular complications, major bleeding events, and stroke in women (48.6\% of overall population) compared with men. However, female sex was found to be an independent predictor of late survival after TAVI [adjusted hazard ratio = 0.79; 95\% confidence interval (CI): 0.73-0.86; \( P = 0.001 \)]\(^{[39]}\). In a meta-analysis including 47,188 patients (49.4\% women), female sex conveyed a lower risk of all-cause mortality at one year [risk ratio (RR) = 0.85; 95\%CI: 0.79-0.91; \( P < 0.001 \)], despite a greater peri-procedural complications rate\(^{[46]}\). Several factors might explain the sex-related differences of clinical outcomes after TAVI and their peculiar time course. Advanced age, low body surface area, and small vessels make women at higher risk for bleeding and vascular complications in the early period after the procedure. Over a longer term, fewer comorbidities, lower occurrence of paravalvular regurgitation and patient-prosthesis mismatch, and a more favorable left ventricular remodeling could drive the survival advantage of women over men. In perspective, changing demographics of patients (younger and at lower risk), device, and procedural amelioration could mitigate the impact of sex on TAVI outcomes. In this regard, an analysis of the nonrandomized PARTNER II S3 trial showed equivalent mortality rates at one year for women and men\(^{[50]}\). Similarly, in a study of 298 patients receiving a new generation transcatheter heart valve [Sapien 3 (Edwards Lifesciences, Irvine, California) or Corevalve Evolut R or Evolut Pro (Medtronic, Minneapolis, Minnesota)], no significant differences were found in postprocedural outcomes including all-cause mortality between women and men\(^{[53]}\).

**TECHNICAL SEX-SPECIFIC CONSIDERATION IN TAVI**

Access management

Vascular complications still represent a relevant concern in TAVI procedures. In intermediate risk patients, major vascular complications (MVC) with third-generation transcatheter heart valves (THV) have an incidence ranging from 6\% to 7.9\%\(^{[52]}\) and are associated with worse clinical outcomes with a prolonged hospital stay, an increased risk of wound infection, and a higher in-hospital mortality\(^{[53]}\). A recent sub-analysis from the WIN TAVI registry has outlined that women experiencing MVC after TAVR are at significantly higher early risk of life-threatening or major bleeding and death and late risk of stroke,
confirming the importance of careful access site management in female patients undergoing TAVI (In press).

**Assessment**

Access site should be thoroughly assessed by multi-slice computed tomography. CT scan can identify the presence of peripheral vascular disease, small size of ilio-femoral vessels, severe tortuosity, and calcifications, conditions that can increase the rate of vascular complications\[^{54}\]. In particular, the extent and distribution of calcifications should be reported in order to plan the use of adjunctive treatments, such as intravascular lithotripsy of peripheral vessels, or the need for an alternative route\[^{55}\]. CT scan is also of utmost importance in the assessment of ilio-femoral vessels dimensions, being the sheath to femoral artery ratio (SFAR) a strong predictor of vascular complications. Female patients might have smaller vessel diameters resulting in an unfavorable SFAR, and this might explain the higher rate of vascular complications observed in this population\[^{56}\]\[^{54}\] [Figure 3]. If transfemoral access is not feasible, alternative peripheral vascular approaches such as transsubclavian/transaxillary/transcarotid/transapical/transaortic/transcaval (in order of importance) may be considered if the risk is deemed high and the patient is inoperable.

**Puncture**

Femoral puncture can be obtained using fluoroscopy guidance with contralateral angiography (FCA) or with the use of two-dimensional ultrasound (2D-US). A recent study reported no difference in the risk of vascular and bleeding complications according to the femoral puncture technique used [FCA vs. 2D-US: 6.7% (95%CI: 4.9%-8.9%) vs. 6.8% (95%CI: 4.8%-9.3%); \(P = 0.63\); 6.1% (95%CI: 4.4%-8.2%) vs. 6.4% (95%CI: 4.8%-9.3%); \(P = 0.70\) respectively]\[^{57}\]. However, it can be speculated that in specific subsets of patients (small vessels and severe calcification), 2D-US guidance might improve patients’ outcomes.

**Closure**

Different vascular closure devices (VCD) have been used in order to reduce vascular complications. In a post hoc analysis from the BRAVO-3 (Bivalirudin vs. heparin anti-coagulation in transcatheter aortic valve replacement) trial, in comparison to the Prostar device (Abbott Vascular, Santa Clara), the use of two Proglide devices (Abbott Vascular, Santa Clara) was associated with a lower rate of major or minor vascular complications and lower rates of acute kidney injury in patients undergoing transfemoral TAVI\[^{58}\]. In line with these results, the recent sub-analysis from the WIN TAVI Registry identified the use of Proglide as an independent predictor of reduction of MVC [hazard ratio (HR) = 0.49; 95%CI: 0.28-0.84; \(P = 0.010\)] (In press). Moreover, to increase the safety of the percutaneous closure of the primary TAVI access, the radial modified crossover technique for controlled angiography and balloon inflation of the therapeutic access site might be used\[^{59}\].

In conclusion, women undergoing TAVI experience more vascular complications than their male counterparts. MVC is related to worse clinical outcomes. A careful CT scan access assessment along with the use of US in selected cases, a minimalistic approach with a “diagnostic” radial access, and the adequate use of VCD for percutaneous closure of the primary access might reduce the incidence of MVC and improve patient outcomes.

**Device selection**

In recent years, the continuous technological evolution guided by a growing clinical experience has led to the development of new iterations of preexisting THV platforms and newly designed THV systems, with subsequent improvement in valve hemodynamic and reduction in procedural complications. Moreover, with the advent of multimodal three-dimensional imaging (in particular, CT scan) as the gold standard in
the screening of TAVI candidates, a lot of anatomical-clinical correlations have become more and more evident, affording the opportunity to select the most appropriate device for each individual anatomy (and patient), according to a tailored, patient-centered modern concept of medicine\textsuperscript{[60-64]}. The possible different choice of THV between a male and a female patient affected by AS is related to different anatomical characteristics and peculiar pathophysiological features of AS according to sex, as previously detailed. Women, compared with men, present with particular recurring anatomical characteristics, on which we try to focus on guiding the choice of the prosthesis in particular circumstances. Recurrent anatomical characteristics among women affected by AS are the presence of a small body surface area, small anatomic root (including small annulus, sinus of Valsalva, and sino-tubular junction), low coronary take off, and small ilio-femoral vessels. Moreover, accumulating evidence suggests that, in patients with degenerative AS, sex can determine important differences in the pathophysiological processes of development and progression of AS, leading to a higher prevalence of fibrosis than calcification in stenotic aortic valves of female patients in comparison to men. Similar differences are also present at the ventricular level, with more pronounced cardiac hypertrophy and fibrosis in women than men, which translates into concentric hypertrophic LV remodeling with small and hypertrophic LV cavity, more frequent paradoxical LFLG AS phenotypes, and final development of heart failure with preserved ejection fraction\textsuperscript{[8]}.

Considering all these anatomical features, it is possible to speculate which THVs might have potential advantages in women.

\textit{Aortic root anatomy, risk of prosthesis patient mismatch, and coronary occlusion}

First, on the basis of the manufacturer’s recommendations, the THVs that cover the smallest annular dimension (\(< 21\) mm) are CoreValve iterations (Evolut R, Pro and Pro+, Medtronic, Minneapolis, Minnesota), Edwards Sapien 3/Ultra (Edwards LifeSciences, Irvine, CA, USA), Myval (Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India), Portico/Navigator Valve (Abbott Structural Heart, St Paul, MN, USA), and Allegra valve (New Valve Technology, Hechingen, Germany). Differently, Acurate Neo and Neo 2 valve (Boston Scientific, Marlborough, MA, USA) are not indicated, according to the sizing chart, for mean annulus diameter \(< 21\) mm\textsuperscript{[63]}. Moreover, small annuli bear the risk of high residual post-procedural gradients and patient-prosthesis mismatch (PPM). Thus, as a general principle, the use of THVs with supra-annular leaflet attachment, such as CoreValve iterations, may be advantageous in such anatomies, allowing to achieve the best hemodynamic performances\textsuperscript{[61]}. In the CHOICE-Extend registry which included new...
generation devices, Sapien 3 THVs yielded smaller effective orifice area (EOA) and a higher residual gradient than Evolut R THVs, and multivariate regression analysis revealed that the use of the Evolut R was significantly associated with a lower risk for PPM, especially in patients with small annuli < 23 mm\(^6\). In addition, in the Ocean TAVI registry, Evolut R seems to be superior to Sapien 3 in hemodynamic performance for patients with a small annulus (< 23 mm) up to one year after TAVI (mean prosthesis gradient 9.0 mmHg vs. 12.0 mmHg; \(P < 0.001\) and index EOA 1.20 cm\(^2\)/m\(^2\) vs. 1.08 cm\(^2\)/m\(^2\), \(P < 0.001\), with a lower incidence of moderate PPM (6.9% vs. 28.4%; \(P = 0.015\)) in the extremely small annulus-matched cohort (< 21 mm). Nevertheless, severe prosthesis-patient mismatch and all-cause mortality at one year were similar between the two groups\(^6\). The supra-annular designed self-expandable ACURATE neo valve also resulted in lower transvalvular gradients compared with the SAPIEN 3 Valve (mean gradient 7 mmHg vs. 11 mmHg; \(P < 0.0001\), as shown in the SCOPE I randomized trial and in another multicenter propensity-matched analysis reporting less PPM with Acurate Neo compared to SAPIEN 3 in patients with an aortic annulus area < 400 mm\(^2\)\(^6\),\(^7\).

The particularly favorable hemodynamic performance granted by supra-annular devices could theoretically be an advantage not only in small anatomies but also in the case of paradoxical LFLG AS, when it is of utmost importance to implant a device with the best hemodynamic performance possible. Paradoxical LFLG AS is described in about 10% of TAVI patients in large real-world registries, and it is more frequently encountered in female patients. There is evidence supporting a similar mid-term prognosis after TAVI procedure in paradoxical LFLG patients than in high gradient AS patients, despite higher perioperative mortality; however, the impact of device selection in this condition is hypothesized and still has to be demonstrated\(^6\).

Regarding the risk of acute coronary occlusion after TAVI, this rare complication is described more frequently in women, in patients receiving a balloon-expandable valve, and in those with a previous surgical bioprosthesis; lower-lying coronary ostium and shallow sinus of Valsalva were associated anatomic factors\(^8\). In cases where the risk of coronary occlusion is considered significant, the availability of repositionable/retrievable TAVI systems should be considered. However, all these potential advantages of supra-annular self-expandable devices must always be counterbalanced by the lower rate of selective coronary cannulation described with these THVs\(^8\). Reasons for impaired coronary selective cannulation with supra-annular devices are the taller-frame design, higher leaflets’ position, and asymmetric skirt, which might hinder coronary access if a commissural post is placed in front of a coronary ostium. Even if this issue could be mitigated by commissural alignment technique during valve deployment, nevertheless, in patients with concomitant coronary artery disease, small sino-tubular junction, and in younger patients, when the need for future TAVI-in-TAVI is likely expected, a short frame balloon-expandable device (Sapien iterations or Myval) should be advised\(^8\).

**Small ilio-femoral vessels and risk of vascular complications**

Finally, frailty and small body surface area oriented the choice towards lower profile THVs family, more adapted to the small iliofemoral diameters. The CoreValve Evolut R and now also the new generation Evolut Pro+ can be implanted using the InLine” (Medtronic) sheath with 14 Fr outer diameter equivalent (minimum vessel diameter requirements 5.0 mm for sizes 23, 26, and 29 mm, in the absence of circumferential calcification). In addition, the last generation low-profile delivery system FlexNav (Abbott), designed for Portico and Navitor valve (Abbott), provides the same low insertion profile (access down to 5.0 mm vessels). Specifically, the FlexNav DS features a hydrophilic-coated, integrated sheath to minimize vessel trauma at the access site. This technological improvement allowed reducing the insertion force and increasing deliverability respect to Evolut Pro valve with Enveo Pro. The rate of access site-related major
vascular complications obtained with FlexNav DS is below 5% in a cohort of high-risk/extreme-risk subjects treated with this device: this compares very well to the low-risk cohort of patients enrolled in the Evolut low-risk trial and in Partner 3 trial (rate of major vascular complications of 3.8% and 2.0%, respectively)\[73\]. The Sapien 3/Ultra THVs can be implanted using a dedicated 14 or 16 Fr expandable eSheath technology, which temporarily expands as the device passes through the iliofemoral vessels (minimum diameter 5.5 mm for size 20, 23, and 26 mm) and then recoils to its smaller caliber. All details about annulus covering range, delivery sheath size, and minimum vessels diameter requirements for different THVs are provided in Figure 4\[63,74\].

Procedural tricks

While performing a TAVI in women, several precautions related to the anatomical specificities discussed above should be kept in mind [Figure 5].

First, the risk of major complications is higher and is associated with worse prognosis\[51,52\]. The small vascular diameter and the calcifications are two of the major reasons for these complications. Efforts should be made to optimize vascular assessment on CT scan before the procedure, and an alternative route should be considered if the risk is deemed high. When a femoral access has been selected, while there was no proven advantage of 2D-US over FCA for vascular puncture guidance\[57\], combining both techniques can be considered in some cases to increase procedural safety, preferably using radial modified crossover technique. Prostar should be avoided, probably replaced by the use of two Proglide devices, as discussed above, while awaiting more data regarding the potential advantage of other devices such as Manta in women. In the case of heavy calcifications, intravascular lithotripsy should be considered. Choosing a device with low-profile delivery system, as discussed above, should be privileged. Finally, the risk of venous vascular complications should not be neglected, and over-the-wire rapid pacing should be preferred to the insertion of a temporary pacing probe when possible.

Another important aspect is related to aortic valve and root size and configuration. The combination of small body surface area, small anatomic root, and a low coronary take-off, which are all more frequent in women, should influence the choice of valve type as well as the procedure itself. As discussed above, supra-annular self-expanding valves can help reduce the risk of transvalvular gradient, and commissural alignment should be targeted to allow future coronary arteries catheterization.

Moreover, taking into account the longer life expectancy of women, it is particularly advisable to customize the implantation strategy of supra-annular THV (when selected) in order to foresee future valve re-intervention. Accordingly, the implantation level of the prosthesis should ensue from the trade-off of the pace-maker risk at the first procedure and the sinus sequestration at the future TAVI-in-TAVI intervention. In patients with a high risk of coronary obstruction due to coronary take-off, coronary protection should be realized using the chimney technique, with the catheterization of the jeopardized coronary and positioning a wire and a stent distally, before inserting the valve. The use of transcatheter electrosurgery for aortic leaflet laceration to prevent iatrogenic coronary artery obstruction (BASILICA) is also a promising alternative\[57\].

Finally, a frequent encounter among women is the presence of a small left ventricular cavity which might increase the risk of perforation. Choosing the appropriate wire and, more importantly, the appropriate distal end shape, is paramount to allow safe anchoring into the ventricle. For operators who are used to shaping their own wire tip, a smaller loop should be applied to the distal end. Otherwise, choosing dedicated pre-shaped stiff guidewire with a small curve is a tempting alternative, allowing a safer procedure. For example, the Amplatz Extra-Stiff APEX wire has a double curve design composed of a larger curve with the
A Balloon-expandable devices

<table>
<thead>
<tr>
<th>DEVICE TYPE</th>
<th>SIZE</th>
<th>ANNULUS DIAMETER</th>
<th>ANNULUS AREA</th>
<th>SHEATH SIZE</th>
<th>MVD REQUIREMENTS *</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAPIEN 3 / ULTRA</td>
<td>20</td>
<td>18.6-21 mm</td>
<td>273-345 mm</td>
<td>14 Fr eSheath Introducer</td>
<td>5.5 mm</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td>20.7-23.4 mm</td>
<td>338-430 mm</td>
<td>14 Fr eSheath Introducer</td>
<td>6.0 mm</td>
</tr>
<tr>
<td></td>
<td>26</td>
<td>23.4-26.4 mm</td>
<td>430-546 mm</td>
<td>16 Fr eSheath Introducer</td>
<td>6.0 mm</td>
</tr>
<tr>
<td></td>
<td>29</td>
<td>26.2-29.5 mm</td>
<td>540-680 mm</td>
<td>16 Fr eSheath Introducer</td>
<td>6.0 mm</td>
</tr>
</tbody>
</table>

| MYVAL | 20   | 16-19 mm         | 270-330 mmq  | 14Fr Python – Introducer Sheath | 5.5 mm |
|       | 21.5 | 17.5-20.5 mm     | 314-380 mmq  | 14Fr Python – Introducer Sheath | 5.5 mm |
|       | 23   | 18-22 mm         | 360-440 mmq  | 14Fr Python – Introducer Sheath | 5.5 mm |
|       | 24.5 | 19.5-23.5 mm     | 410-500 mmq  | 14Fr Python – Introducer Sheath | 5.5 mm |
|       | 26   | 21-25 mm         | 460-560 mmq  | 14Fr Python – Introducer Sheath | 5.5 mm |
|       | 27.5 | 22.5-26.5 mm     | 510-630 mmq  | 14Fr Python – Introducer Sheath | 5.5 mm |
|       | 29   | 24-28 mm         | 570-700 mmq  | 14Fr Python – Introducer Sheath | 5.5 mm |
|       | 30.5 | 25.5-29.5 mm     | 630-770 mmq  | 14Fr Python – Introducer Sheath | 5.5 mm |
|       | 32   | 27-31 mm         | 700-840 mmq  | 14Fr Python – Introducer Sheath | 5.5 mm |

B Self-expandable devices

<table>
<thead>
<tr>
<th>DEVICE TYPE</th>
<th>SIZE</th>
<th>ANNULUS DIAMETER</th>
<th>ANNULUS PERIMETER</th>
<th>SHEATH SIZE</th>
<th>MVD REQUIREMENTS *</th>
</tr>
</thead>
<tbody>
<tr>
<td>COREVALVE / EVOLUT R / PRO / PRO+</td>
<td>23</td>
<td>18-20 mm</td>
<td>56.6-62.8 mm</td>
<td>14 Fr equivalent (Evolut R/PRO+)</td>
<td>5.0 mm (Evolut R/PRO+) 6.5 mm (Evolut PRO)</td>
</tr>
<tr>
<td></td>
<td>26</td>
<td>20-23 mm</td>
<td>62.8-72.3 mm</td>
<td>16 Fr equivalent (Evolut PRO)</td>
<td>5.5 mm (Evolut PRO)</td>
</tr>
<tr>
<td></td>
<td>29</td>
<td>23-26 mm</td>
<td>72.3-81.7 mm</td>
<td>16 Fr equivalent (Evolut R) 18 Fr equivalent (Evolut PRO+)</td>
<td>5.5 mm (Evolut R) 6.0 mm (Evolut PRO+)</td>
</tr>
<tr>
<td></td>
<td>34</td>
<td>26-30 mm</td>
<td>81.7-94.2 mm</td>
<td>16 Fr equivalent (Evolut R) 18 Fr equivalent (Evolut PRO+)</td>
<td>5.5 mm (Evolut R) 6.0 mm (Evolut PRO+)</td>
</tr>
<tr>
<td>ACURATE NEO / NEO 2</td>
<td>S</td>
<td>21-23 mm</td>
<td>66-72 mm</td>
<td>14 Fr iSLEEVE Introducer</td>
<td>5.5 mm</td>
</tr>
<tr>
<td></td>
<td>M</td>
<td>23-25 mm</td>
<td>72-79 mm</td>
<td>14 Fr iSLEEVE Introducer</td>
<td>5.5 mm</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>25-27 mm</td>
<td>79-85 mm</td>
<td>14 Fr iSLEEVE Introducer</td>
<td>5.5 mm</td>
</tr>
<tr>
<td>PORTICO / NAVITOR</td>
<td>23</td>
<td>19-21 mm</td>
<td>60-66 mm</td>
<td>14 Fr equivalent</td>
<td>5.0 mm</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>21-23 mm</td>
<td>66-73 mm</td>
<td>14 Fr equivalent</td>
<td>5.0 mm</td>
</tr>
<tr>
<td></td>
<td>27</td>
<td>23-25 mm</td>
<td>72-79 mm</td>
<td>14 Fr equivalent</td>
<td>5.0 mm</td>
</tr>
<tr>
<td></td>
<td>29</td>
<td>25-27 mm</td>
<td>79-85 mm</td>
<td>14 Fr equivalent</td>
<td>5.0 mm</td>
</tr>
<tr>
<td>ALLEGRA</td>
<td>23</td>
<td>19-22 mm</td>
<td>59.7-69.1 mm</td>
<td>15 Fr equivalent</td>
<td>5.5 mm</td>
</tr>
<tr>
<td></td>
<td>27</td>
<td>22-25 mm</td>
<td>69.1-78.5 mm</td>
<td>15 Fr equivalent</td>
<td>5.5 mm</td>
</tr>
<tr>
<td></td>
<td>31</td>
<td>25-28 mm</td>
<td>78.5-88.0 mm</td>
<td>15 Fr equivalent</td>
<td>5.5 mm</td>
</tr>
</tbody>
</table>

Figure 4. Annulus covering range and vessels diameter requirements of different balloon expandable (A) and self-expandable (B) THVs. *MVD: Minimum vessel diameter requirements (MSCT derived), excluding circumferential Ca²⁺; THVs: transcatheter heart valves; MSCT: multi-slice computed tomography.

distal tip of the wire forming a 2 mm J bend; it can easily maneuver in smaller ventricles, while the Safari2TM wire is available in three different loop sizes, offering the possibility to select the curve size according to the size of the ventricle.

Pharmacological management
The choice of the optimal antithrombotic regimen peri- and post-TAVI is of utmost importance [Figure 6]. Thromboembolic and bleeding complications are frequent and can be potentially life-threatening⁴⁴,⁷⁹,⁸⁶. [Reference]

---

[^1]: Reference 1
[^2]: Reference 2
[^3]: Reference 3
The 2021 ESC/EACTS guidelines recommend life-long single antiplatelet therapy or oral anticoagulation (OAC) in the case of patients who have other indications for OAC, while dual antiplatelet therapy should be administered only in the case of recent percutaneous coronary intervention\(^4\). The 2020 ACC/AHA guidelines recommend life-long low-dose aspirin post-TAVI (IIa), while aspirin plus clopidogrel or vitamin K anticoagulation (VKA) for 3-6 months may be considered in patients with low bleeding risk (IIb)\(^35\). Cohort A of POPular TAVI randomized trial has recently shown a benefit in terms of incidence of bleeding in patients without an OAC indication receiving aspirin alone vs. patients receiving aspirin plus clopidogrel [risk ratio (RR) = 0.57; 95%CI: 0.42-0.77; \(P = 0.001\)], while the composite of cardiovascular death, stroke, or myocardial infarction for aspirin alone was non-inferior to aspirin plus clopidogrel (9.7% and 9.9%, \(P = 0.004\) for non-inferiority)\(^77\). Among patients undergoing TAVI, 40% have an indication for OAC. This subset of patients has been investigated in Cohort B of POPular TAVI trial, where a (novel) oral anticoagulation (N)OAC alone strategy has been compared to a (N)OAC plus clopidogrel for three months. Bleeding was significantly lower with (N)OAC alone vs. (N)OAC plus clopidogrel (21.7% vs. 34.6%; RR = 0.63; 95%CI: 0.43-0.90; \(P = 0.01\)), while the composite of cardiovascular death, stroke, or myocardial

---

**Figure 5.** TAVI procedural tricks according to anatomic considerations among women. FCA: Fluoroscopy guidance with contralateral angiography; 2D-US: two-dimensional ultrasound.

**Figure 6.** Optimal antithrombotic regimen post-TAVI procedure. OAC: Oral anticoagulation; DAPT: dual antiplatelet therapy; ASA: acid acetilsalicilic.
infarction was non-inferior (13.4% and 17.3%, respectively; 95%CI for non-inferiority, -11.9 to 4.0)\[78\]. The results of the recent GALILEO do not support rivaroxaban plus aspirin after TAVI in patients without an OAC indication, while evidence supporting (N)OAC over VKA after TAVI in AF patients is currently lacking\[79\]. The results of these recent trials have been translated in the consensus document from the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions, in collaboration with the ESC Council on Valvular Heart Disease on “management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation”\[80\].

However, no specific recommendations have been indicated for women undergoing TAVI procedures. In both Cohort A and Cohort B from POPular TAVI, almost half of the enrolled patients were women, with no differences among the compared groups. However, no sub-analysis has been carried out to investigate differences in outcomes by sex. Differences between males and females in short- and long-term clinical outcomes of TAVI might exist\[106\]. However, evidence based on randomized studies is lacking, and several small studies yielded non-conclusive results\[48-50,81\]. Data from observational studies suggest sex disparities in antiplatelet and antithrombotic management after TAVI; specifically, women were more likely to be prescribed clopidogrel and less likely to be prescribed warfarin due to lower rates of atrial fibrillation in women. Even though disparities in clinical presentation and procedural management were observed, no significant difference in clinical outcomes was noted\[51\]. A large meta-analysis of registry data published in 2015 demonstrated women had higher rates than men of major bleeding, vascular complications, and stroke following TAVI; however, female sex was independently associated with improved survival at median follow-up of one year\[39\]. A recent meta-analysis of 47,188 patients (49.4% women) including low-risk patients investigated TAVI outcomes by sex. At 30 days, women had more bleeding (P < 0.001), vascular complications (P < 0.001), and stroke/transient ischemic attack (P = 0.02), while no differences emerged in all-cause (P = 0.19) or cardiovascular death (P = 0.91) as compared to men\[49\].

The role of sex in determining the pharmacokinetic and pharmacodynamic responses to antithrombotic medications has already been established\[82\]. Importantly, signals of an increased risk of bleeding in women have been identified, and this aspect deserves clinical attention.

Moreover, female sex is an independent predictor of anemia in patients with severe aortic stenosis\[83\]. The WIN-TAVI registry showed that not only is anemia a common finding in elderly females, but it is also strongly related to the long-term prognosis. Nevertheless, patients with severe anemia were more likely to be discharged on oral anticoagulants than those with mild-to-moderate or no anemia, partially explained by the higher prevalence of peripheral artery disease\[84\]. Therefore, in the case of OAC therapy, particular attention has to be paid to hemoglobin values, and an accurate revaluation of the thrombotic and bleeding risks might be suggested during follow up. As bleeding and vascular complications are essential issues for women undergoing TAVI, antithrombotic and anticoagulant therapy should be established, paying particular attention to patients’ characteristics, presence of comorbidities, and polytherapy that may predispose to bleeding and thrombosis. Additionally, a greater awareness of sex-related issues in antithrombotic and anticoagulant therapy should be promoted among physicians, and further evidence from large clinical trials looking at the safety and efficacy balance of different antithrombotic strategies in women is warranted to better inform the therapeutic decision making in daily clinical practice.

CONCLUSIONS

Unsolved issues and future directions

Different pathophysiology, baseline and morphological characteristics, clinical presentation, and outcomes have been observed in women with AS undergoing TAVI. However, differently from ischemic heart disease
trials, female patients represent in general half of the patients treated with TAVI in clinical studies.

Nevertheless, the impact of sex in female patients with AS has not been still well evaluated and taken into appropriate consideration. Clinical studies designed specifically on the peculiarities of female patients with AS treated with TAVI are then warranted in order to tailor the treatment on those peculiarities.

Currently, the “Randomized research in womEn All Comers With Aortic Stenosis” trial is ongoing and randomizing female patients with AS to receive either TAVI or aortic valve replacement indication for AVR. The study assumes that from available scientific data in female patients, TAVI is not inferior to AVR in the study primary end points.

DECLARATIONS

Authors’ contributions
Participated in drafting, revising and approval of the manuscript submitted: Masiero G, Paradies V, Franzone A, Bellini B, De Biase C, Karam N, Sanguineti F, Eltchaninoff H, Fraccaro C, Chieffo A

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflict of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES


60. Renker M, Kim WK. Choice of transcatheter heart valve: should we select the device according to each patient’s characteristics or should it be “one valve fits all”? *Ann Transl Med* 2020;8:961. DOI: PubMed

